
Manipal Health Enterprises Limited
IPO Summary (PrEqt)
Manipal Health Enterprises operates one of India’s largest multi-specialty hospital networks, with 49 hospitals and 13,037 licensed beds. FY26 consolidated revenue was INR 10,335.75 Cr, adjusted EBITDA INR 2,644.1 Cr and PAT INR 916.5 Cr. Its INR 9,275.2 Cr IPO comprises an INR 8,000 Cr fresh issue and an OFS of 21.61 million shares. Fresh proceeds will chiefly repay acquisition debt and complete the Sahyadri stake purchase; leverage, integration and occupancy remain the key monitorables.
IPO Review and Rating
Building Healthier Communities Through Trusted and Accessible Medical Care
The IPO is priced near or above peer earnings multiples and at a high price-to-book multiple. The valuation is not cheap, but the large fresh issue and expected deleveraging provide a credible route to higher PAT and return ratios. Manipal operates in a structurally growing market but not a high-growth technology sector. Its scale and brand are attractive, while the fragmented competitive structure and heavy regulatory burden reduce the mechanical industry score.
Detailed Analysis
Revenue from operations increased from INR 6,171.63 Cr in FY24 to INR 8,242.25 Cr in FY25 and INR 10,335.75 Cr in FY26, representing a two-year CAGR of 29.41%
EBITDA excluding exceptional items increased from INR 1,776.60 Cr in FY24 to INR 2,795.94 Cr in FY26. FY26 EBITDA margin was 27.05%
PAT was INR 533.20 Cr in FY24, INR 1,081.67 Cr in FY25 and INR 916.52 Cr in FY26. FY26 PAT margin declined to 8.87% from 13.12% in FY25
FY26 gross borrowings were approximately INR 10,553.43 Cr, compared with total equity of INR 8,798.76 Cr, producing gross debt-to-equity of approximately 1.20x
FY26 RoNW was 10.57%, compared with 18.16% in FY25 and 14.75% in FY24
Operating cash flow was positive at INR 1,388.65 Cr in FY24, INR 1,569.83 Cr in FY25 and INR 2,078.40 Cr in FY26
Detailed Analysis
The Indian healthcare-delivery market was approximately INR 700,000 Cr in FY25 and is estimated at INR 760,000–780,000 Cr in FY26. It is projected to reach INR 1,120,000–1,220,000 Cr by FY30, representing a CAGR of 10 -12%
The organised private-hospital sector is classified as a growth-stage industry. The market is established, but private players continue expanding capacity, acquiring regional chains and increasing their share of healthcare delivery
The Indian hospital market remains highly fragmented, with large private hospital chains representing only approximately 20% of the total market in FY26
Hospitals require registrations, minimum clinical standards, regulated procedure-rate disclosures and state-specific approvals. Operations are also subject to radiation safety, medical-device, biomedical-waste, pharmacy and patient-protection regulations
Detailed Analysis
Dr. Ranjan Pai has served on Manipal’s Board since 2010 and has board exposure to listed companies including Dr. Agarwal’s Health Care and United Breweries. Managing Director and CEO Dilip Jose has served as a director since 2017
The Board has nine directors, of whom three are independent, representing exactly 33.33% of the Board
No promoter shares are pledged. However, Dr. Ranjan Pai has received ED summons seeking historical financial information and is involved in a customs show-cause matter concerning an aircraft. The RHP reports no promoter criminal or material civil litigation
Revenue-linked related-party hospital services were immaterial and comfortably below 5% of revenue. One disclosed hospital-services transaction was approximately INR 1.10 Cr. The Company has also entered into a perpetual brand-licensing arrangement settled through issuance of 23,820,811 shares to a promoter-group entity
At the upper price band, the IPO consists of a fresh issue of INR 8,000.00 Cr and an OFS of approximately INR 1,275.22 Cr. Promoters and promoter-group shareholders are participating in the OFS, but the IPO is approximately 86.25% fresh capital
Detailed Analysis
At INR 590 per share and FY26 diluted EPS of INR 7.67, the issue is valued at approximately 76.92x earnings. The RHP reports an average peer P/E of 70.31x, with a range of 66.15–74.55x
Estimated post-issue market capitalisation at INR 590 is approximately INR 77,605.68 Cr. After accounting for the proposed debt repayment, estimated post-issue EV is approximately INR 81,942.03 Cr, implying EV/adjusted EBITDA of approximately 30.99x. Current peer multiples are approximately 33.5x for Apollo, 45.25x for Max and around 35.24x for Fortis
FY26 NAV was INR 72.55 per share. At INR 590, the issue is valued at approximately 8.13x book value
Detailed Analysis
The syndicate contains leading domestic and global investment banks with extensive institutional distribution and execution capacity
₹560.0 to ₹590.0
₹-7.0
-1.2%
25.0 Shares
| Issue size | |
|---|---|
| Overall | ₹9,275.0 Cr |
| Fresh Issue | ₹8,000.0 Cr |
| Offer for Sale | ₹1,275.0 Cr |
Minimum Investment
₹14,750.0 / 625 shares

Merchant Banker
Kotak Mahindra Capital Co.Ltd.
IPO Document
RHP / Anchor Document
29th Jul 2026
31st Jul 2026
₹77,605.7 Cr
₹10,520.5 Cr
₹916.5 Cr
₹9,275.0 Cr
Face Value
₹ 2.0Offer Price
₹ 590.0Lot Size
25.0 sharesSale Type
Fresh capital cum OFSPAT FY'26
₹ 916.5 CrPAT Margin (FY'26)
8.9 %P/E MultiplePre IPO Multiple
75.9xEBITDA (FY'25)
₹ 2,795.9 CrCAGR Growth 3Y
29.6 %ROCE (FY'26)
21.9 %Price to Book Value
8.1xDebt/Equity
1.2xCompany Website
www.manipalhospitals.comExplore new deals
Overview
Fund Allocation
Total: ₹0 CrTimeline
Business
Beds
Business Model
Geographical Presence
Sales Channel
Financial Highlights
Income Statement
Revenue growth with EBITDA and PAT margins
| Financial Metric | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Revenue (₹ Cr) | 6,265.2 | 8,362.8 | 10,520.5 |
| Growth (%) | 27.5% | 33.5% | 25.4% |
| EBITDA (₹ Cr) | 1,776.6 | 2,247.1 | 2,795.9 |
| EBITDA Margin (%) | 28.8% | 27.3% | 27.0% |
| PAT (₹ Cr) | 533.2 | 1,081.7 | 916.5 |
| PAT Margin (%) | 8.6% | 13.1% | 8.9% |
OBSERVATIONS & INSIGHTS
Corporate relationships, health checks, international-patient desks and regional outreach broaden the acquisition funnel
EBITDA excluding exceptional items increased 24.43% to INR 2,795.9 Cr in FY26
EBITDA margin moderated from 27.26% to 27.05%, remaining broadly stable despite integration activity
PAT declined 15.27% to ₹916.52 crore as finance costs and depreciation increased materially
PAT margin declined from 13.12% in FY25 to 8.87% in FY26; adjusted operating metrics provide a clearer view of underlying hospital performance
Balance Sheet
| Financial Metric | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Net Worth | ₹ 4,087.5 Cr | ₹ 6,000.2 Cr | ₹ 8,798.8 Cr |
| Total Assets | ₹ 10,818.8 Cr | ₹ 14,072.1 Cr | ₹ 24,864.5 Cr |
| Total Borrowing | ₹ 3,944.0 Cr | ₹ 4,766.8 Cr | ₹ 10,553.4 Cr |
| Reserves & Surplus | ₹ 3,953.6 Cr | ₹ 5,788.6 Cr | ₹ 8,205.0 Cr |
OBSERVATIONS & INSIGHTS
Total assets increased 76.7% from INR 14,072.1 Cr in FY25 to INR 24,864.5 Cr in FY26, reflecting the enlarged hospital portfolio
Non-current borrowings more than doubled to ₹9,948.81 crore, largely reflecting acquisition financing
Cash Flow
| Financial Metric | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
CFO (₹ Cr) Cash generated from core business operations. | +1,388.6 Cr | +1,569.8 Cr | +2,078.4 Cr |
CFI (₹ Cr) Cash used for investments and long-term assets. | -870.5 Cr | -2,658.3 Cr | -7,036.7 Cr |
CFF (₹ Cr) Cash flow related to funding and borrowings. | -250.2 Cr | +904.1 Cr | +4,954.4 Cr |
Financial Ratios
OBSERVATIONS & INSIGHTS
ROCE declined from 26.9% in FY25 to 21.9% in FY'26 as the capital base expanded ahead of full earnings contribution
Debt-to-equity increased to approximately 1.2x as consolidated borrowings more than doubled
Current ratio declined from 1.6x to 1.2x due to the enlarged current-liability base
Interest coverage fell to approximately 2.4x, making debt repayment the most important near-term financial objective
Industry Overview
Industry Drivers
Structural Bed Shortage and Rising Disease Burden
India continues to face a material shortage of hospital beds and uneven access to quality tertiary care, particularly outside major metros. Population growth, ageing, urbanisation and the increasing incidence of non-communicable diseases are raising demand for specialised treatment and long-duration care. Organised hospital chains can benefit by adding capacity in underserved catchments and by developing referral networks across tiers of cities.
The key factors are:
India has about 16 hospital beds per 10,000 people compared with a global average of roughly 33
Non-metro bed density is lower at approximately 14 beds per 10,000 people
Cardiac disease, cancer, diabetes, renal disease and neurological conditions require specialised hospital infrastructure
Cardiac disease, cancer, diabetes, renal disease and neurological conditions require specialised hospital infrastructure
Large hospital networks can route patients across primary, secondary and tertiary centres through hub-and-spoke systems

Insurance Penetration and Improved Healthcare Affordability
Healthcare affordability is improving as private insurance, government schemes and employer-sponsored coverage expand. A larger insured population reduces out-of-pocket barriers for complex procedures and supports higher utilisation of organised hospitals. However, the benefit is accompanied by insurer-negotiated tariffs, claims administration and longer collection cycles that hospitals must manage carefully.
The key factors are:
Health-insurance penetration increased from approximately 35% in FY19 to about 41% in FY25
Private insurers and TPAs accounted for 49.68% of Manipal Health’s FY26 revenue
Government schemes accounted for 13.80% of FY26 revenue and broaden access to hospital care
Employer and corporate programmes support demand for diagnostics, elective treatment and preventive health checks

Consolidation and Non-Metro Expansion
The Indian hospital industry remains fragmented, while larger chains have access to capital, clinical talent, procurement scale and centralised technology. This creates opportunities to acquire regional platforms and expand into cities where quality private healthcare capacity remains limited. Successful consolidation can improve occupancy, specialty mix and purchasing economics, but integration discipline is critical.
The key factors are:
Large private hospital chains account for a limited share of the overall healthcare delivery market
Regional hospitals often possess strong local brands and referral networks but lack capital for expansion
Acquisitions allow entry into established catchments faster than greenfield construction
Non-metro facilities can generate attractive demand where bed availability and specialist access are constrained
Central procurement, common clinical protocols and shared digital systems can improve efficiency after integration

Complex Care, Medical Technology and Digital Health
Hospital growth is increasingly driven by high-acuity specialties, advanced diagnostics, robotic and minimally invasive surgery and digitally connected patient journeys. These services require specialised clinicians and significant capital investment but support higher revenue per occupied bed and stronger clinical differentiation. Integrated digital systems also improve appointment access, care coordination and capacity utilisation.
The key factors are:
Cardiac, oncology, neuro, gastro, orthopaedic and renal specialties contributed 61.5% of FY26 gross inpatient revenue
Advanced procedures and complex case mix can increase ARPOB and strengthen hospital brand positioning
Digital appointment, electronic medical record and patient-engagement platforms improve access and continuity
Teleconsultation and home-care services extend the hospital relationship beyond physical facilities
Clinical technology investments require utilisation discipline to generate adequate returns on capital

Risks in the Industry
Hospital operations are highly regulated, capital intensive and dependent on specialist doctors, nurses and clinical infrastructure. Revenue can be affected by occupancy, payor tariffs, procedure mix and regulatory controls, while greenfield and acquisition-led expansions may take time to reach mature margins. Strong quality systems, clinical governance and working-capital management are therefore essential.
The key details are:
Shortages of doctors, nurses and technicians can increase employee and professional costs
Government or insurer price controls can limit realisations for selected procedures and patient categories
Insurance and government receivables can lengthen cash-conversion cycles and create claim-disallowance risk
New hospitals have high fixed costs and may require several years to reach targeted occupancy
Clinical incidents, infection control failures or data-security breaches can damage reputation and create liability

Government Policy Support
Public policy is focused on expanding healthcare access, insurance coverage, digital health infrastructure and domestic medical capability. Programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission can expand patient access and improve interoperability, while infrastructure and medical-education initiatives support long-term capacity creation. Policy support remains subject to reimbursement rates, implementation quality and state-level execution.
The key details are:
PM-JAY and state health schemes increase access to hospital treatment for eligible beneficiaries
The Ayushman Bharat Digital Mission supports digital health IDs and interoperable health records
Government programmes for medical colleges and health infrastructure can expand the clinical workforce and referral base
Medical-visa and tourism initiatives support international-patient flows to Indian hospitals
Incentives for domestic medical devices and pharmaceuticals can improve availability of healthcare inputs over time

Fundraise/Future Plans
Shareholding
Pre-issue shareholding
Promoter Holding 0.0%
Post-Issue Shareholding
Promoter Holding 0.0%
- Overview
- Business
- Financial Highlights
- Industry Overview
- Fundraise/Future Plans
- Documentation

